LEADER 01433nam  2200385Ia 450 
001 9910699060503321
005 20090818141011.0
035   $a(CKB)5470000002399280
035   $a(OCoLC)430960220
035   $a(EXLCZ)995470000002399280
100   $a20090818d2005      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $edevelopment and use of risk minimization action plans
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2005]
215   $a1 online resource (23 pages)
300   $a"Center for Biologics Evaluation and Research (CBER)".
300   $a"Clinical medical".
300   $a"March 2005".
517   $aGuidance for industry 
606   $aDrugs$xSide effects$xPrevention$xGovernment policy$zUnited States
606   $aBiologicals$xGovernment policy$zUnited States
615  0$aDrugs$xSide effects$xPrevention$xGovernment policy
615  0$aBiologicals$xGovernment policy
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699060503321
996   $aGuidance for industry$93434577
997   $aUNINA